Skip to main content

MediaCenter Panda Security

MediaCenter Panda Security

Panda Security continues to expand internationally through organic growth and innovation as it celebrates its 25th anniversary #Panda25years

Posted: 25 Jun 2015 01:21 AM PDT

Panda Security has reason to celebrate. Today the multinational developer of security solutions designed to protect the digital lives of individuals and organizations alike  is celebrating  25 years in the vanguard of IT security, not just in its native Spain, but all around the globe. Panda Security, with a direct presence in more than 80 countries and products distributed in around 200, has announced that Italy and Denmark are set to join its network of subsidiaries, as two important markets for the company's European business. With these latest additions, the company now has 16 subsidiaries:  Austria, Belgium, Brazil, Canada, Denmark, Finland, France, Germany, Holland, Italy, Mexico, Portugal, Spain, Sweden, United Kingdom, and the U.S.A.

This internationalization process, which represents one of the pillars of the company's four-year strategic plan, is further bolstered by the consolidation of its presence in markets where it is already strong, -Western Europe, the USA, Latin America-, for example with the recent inclusion of Panama in its 'Country Partner' model.

Moreover, in the coming months, Panda's international expansion plan will also see it strengthen its position in emerging markets such as China, Russia and India.

New strategy for the 25th anniversary

In the year of its 25th anniversary the company has adopted a new corporate identity that reflects Panda's commitment to simplifying the apparently complex, through the concept of 'Simplexity'. This concept underpins the company's effort to provide new and improved solutions to safeguard users' digital lives.

"Our mission is to offer users a simple, fast and effective solution, which is always the product of our innovation. Throughout these 25 years, Panda has never ceased to innovate and to be in the vanguard of technology. We are positioned as visionaries with the implementation of technologies like Cloud Computing or Big Data Analytics which were totally disruptive some years ago. Now we are looking ahead to another 25 years with energy and enthusiasm, and with the certainty that we have all the resources we need to continue leading the way", explains Diego Navarrete, CEO of Panda Security.

25th anniversary

Diego Navarrete, CEO of Panda Security

The company is set to embark on a four-year strategic plan, centered on internationalization, on maintaining the pace of growth –both of sales and product portfolio–, and on driving forward new technologies and strategic alliances that respond to market trends such as the Internet of things, Big Data, Cloud Computing or mobility.

To celebrate its 25th anniversary, Panda Security has prepared an infographic outlining the major milestones from the company's history, which you can download here.

 

The post Panda Security continues to expand internationally through organic growth and innovation as it celebrates its 25th anniversary #Panda25years appeared first on MediaCenter Panda Security.

Comments

Post a Comment

Popular posts from this blog

The first drug for a common, deadly liver disease is here – and more are coming

VIEW IN BROWSER | SUBSCRIBE TUE, MAR 19, 2024 EDITOR'S NOTE     Think a friend or colleague should be getting this newsletter? Share this link with them to sign up.   Good morning!  Millions of Americans with a common and potentially life-threatening form of liver disease will soon have access to the first-ever treatment for the condition.    In a landmark decision on Thursday, the Food and Drug Administration approved Madrigal Pharmaceuticals ' drug " Rezdiffra ," to be used along with diet and exercise. The company expects the medicine to be available next month with a hefty price tag of $47,400 per year before insurance and other rebates.    So, why is this approval so important?    First of all, people suffering from the disease badly need a treatment. Rezdiffra is specifically approved to treat patients with nonalcoholic steatoh
Post a Comment
Read More

J&J, Merck and Bristol Myers Squibb are in the hot seat

VIEW IN BROWSER | SUBSCRIBE TUE, JAN 30, 2024 EDITOR'S NOTE     Think a friend or colleague should be getting this newsletter? Share this link with them to sign up.   Good afternoon! This is Annika Kim Constantino, and I cover the biotech and pharmaceutical industry for CNBC.com .    Three names in the industry – Johnson & Johnson, Merck and Bristol Myers Squibb – face a pivotal few weeks ahead.    CEOs from those companies are slated to testify at a Senate hearing on high prescription drug prices in the U.S. on Feb. 8 at 10 a.m. ET, Sen. Bernie Sanders announced Friday.   It took subpoena threats from the senator, but J&J CEO Joaquin Duato and Merck CEO Robert Davis have agreed to testify after both executives declined earlier requests to appear at the Senate HELP committee's hearing. They join Bristol Myers Squibb CEO Chris Boerner, who agr
Post a Comment
Read More

How competitive can Roche be in the weight loss drug market?

VIEW IN BROWSER | SUBSCRIBE TUE, SEP 17, 2024 EDITOR'S NOTE     Think a friend or colleague should be getting this newsletter? Share this link with them to sign up. Good afternoon!  Roche is one of several drugmakers hoping to join the booming weight loss drug market, which Novo Nordisk and Eli Lilly are currently dominating. But can the Swiss company develop drugs that can compete with that duopoly?  The answer isn't clear yet.  We need to see more data from longer and larger clinical trials, which will likely take years for Roche to conduct.  But the company last week presented more early-stage data more early-stage data on its experimental obesity injection and pill, which some analysts said raised concerns about how competitive those products can be if they enter the space. Some analysts said the new results showed that both drugs – which Roche acquired through its nearly $3 billion acquisition of Carmot Therapeutics in December – caused a higher rate of side
Post a Comment
Read More